Alteration of tooth movement by reveromycin A in osteoprotegerin-deficient mice

Osteoprotegerin-deficient mice develop severe high-turnover osteoporosis with porous low-density trabecular bone from an age-related increase in osteoclast activity and are useful alveolar bone models of osteoporosis or frail periodontal tissue. Bisphosphonate (BP), a first-line drug for osteoporosi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:American journal of orthodontics and dentofacial orthopedics 2020-05, Vol.157 (5), p.680-689
Hauptverfasser: Minamoto, Chisato, Miyazawa, Ken, Tabuchi, Masako, Hirano, Miyuki, Mizuno, Manami, Yoshizako, Mamoru, Torii, Yasuyoshi, Asano, Yuichirou, Sato, Takuma, Kawatani, Makoto, Osada, Hiroyuki, Maeda, Hatsuhiko, Goto, Shigemi
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 689
container_issue 5
container_start_page 680
container_title American journal of orthodontics and dentofacial orthopedics
container_volume 157
creator Minamoto, Chisato
Miyazawa, Ken
Tabuchi, Masako
Hirano, Miyuki
Mizuno, Manami
Yoshizako, Mamoru
Torii, Yasuyoshi
Asano, Yuichirou
Sato, Takuma
Kawatani, Makoto
Osada, Hiroyuki
Maeda, Hatsuhiko
Goto, Shigemi
description Osteoprotegerin-deficient mice develop severe high-turnover osteoporosis with porous low-density trabecular bone from an age-related increase in osteoclast activity and are useful alveolar bone models of osteoporosis or frail periodontal tissue. Bisphosphonate (BP), a first-line drug for osteoporosis, is bone-avid, causing side effects such as brittle and fragile bones and jaw osteonecrosis after tooth extraction. In orthodontics, active movement is precisely controlled by temporarily suppressing and resuming movement. BP impedes such control because of its long half-life of several years in bone. Therefore, we investigated the novel osteoclast-specific inhibitor reveromycin A (RMA), which has a short half-life in bone. We hypothesized that tooth movement could be precisely controlled through temporary discontinuation and re-administration of RMA. Osteoprotegerin-deficient mice and wild-type mice were developed as tooth movement models under constant orthodontic force. A constant orthodontic force of 10 g was induced using a nickel-titanium closed coil spring to move the maxillary first molar for 14 days. We administered BP (1.25 mg/kg) or RMA (1.0 mg/kg) continuously and then discontinued it to reveal how the subsequent movement of teeth and surrounding alveolar bone was affected. Continuous BP or RMA administration suppressed osteoclast activity and preserved alveolar bone around the roots, apparently normalizing bone metabolism. Tooth movement remained suppressed after BP discontinuation but resumed at a higher rate after discontinuation of RMA. RMA appears useful for controlling orthodontic tooth movement because it can be suppressed and resumed through administration and discontinuation, respectively. •Osteoprotegerin-deficient mice are alveolar bone models of osteoporosis or frail periodontal tissue.•Mice were developed as tooth movement models under constant orthodontic force.•Continuous reveromycin A (RMA) administration suppressed osteoclast activity.•RMA has a short half-life in bone.•RMA appears useful for controlling orthodontic tooth movement.
doi_str_mv 10.1016/j.ajodo.2019.04.037
format Article
fullrecord <record><control><sourceid>proquest_webof</sourceid><recordid>TN_cdi_proquest_miscellaneous_2397688569</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0889540619309679</els_id><sourcerecordid>2397688569</sourcerecordid><originalsourceid>FETCH-LOGICAL-c425t-aa09e3b7f7f24e6f62cbc9adcb72e8dcc0c44344bfd94305549ebfe042766653</originalsourceid><addsrcrecordid>eNqNkU1r2zAYgMXoWNNuv6BQfCwMe68-bR12CKFbB4Veehe2_GpTiK1OUlLy76s0WY9lF0mH59HHI0KuKDQUqPq2bvp1GEPDgOoGRAO8_UAWFHRbq1ayM7KArtO1FKDOyUVKawDQgsEncs4Zl0IIuiAPy03G2Gcf5iq4KoeQ_1RT2OGEc66GfRVxhzFMe-vnalmVIaSM4SmGjL8x-rke0XnrD_TkLX4mH12_SfjlNF-Sxx-3j6u7-v7h56_V8r62gslc9z1o5EPrWscEKqeYHazuRzu0DLvRWrBCcCEGN2rBQUqhcXAIgrVKKckvyc1x23KRv1tM2Uw-Wdxs-hnDNhnGdau6TipdUH5EbQwpRXTmKfqpj3tDwRxCmrV5DWkOIQ0IU0IW6_p0wHaYcHxz_pUrwNcj8IxDcOlQwOIbVlJLpkFxWlaUFbr7f3rl8-uHrMJ2zkX9flSx5Nx5jOakjz6izWYM_t2XvAAddacR</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2397688569</pqid></control><display><type>article</type><title>Alteration of tooth movement by reveromycin A in osteoprotegerin-deficient mice</title><source>Web of Science - Science Citation Index Expanded - 2020&lt;img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /&gt;</source><source>Access via ScienceDirect (Elsevier)</source><creator>Minamoto, Chisato ; Miyazawa, Ken ; Tabuchi, Masako ; Hirano, Miyuki ; Mizuno, Manami ; Yoshizako, Mamoru ; Torii, Yasuyoshi ; Asano, Yuichirou ; Sato, Takuma ; Kawatani, Makoto ; Osada, Hiroyuki ; Maeda, Hatsuhiko ; Goto, Shigemi</creator><creatorcontrib>Minamoto, Chisato ; Miyazawa, Ken ; Tabuchi, Masako ; Hirano, Miyuki ; Mizuno, Manami ; Yoshizako, Mamoru ; Torii, Yasuyoshi ; Asano, Yuichirou ; Sato, Takuma ; Kawatani, Makoto ; Osada, Hiroyuki ; Maeda, Hatsuhiko ; Goto, Shigemi</creatorcontrib><description>Osteoprotegerin-deficient mice develop severe high-turnover osteoporosis with porous low-density trabecular bone from an age-related increase in osteoclast activity and are useful alveolar bone models of osteoporosis or frail periodontal tissue. Bisphosphonate (BP), a first-line drug for osteoporosis, is bone-avid, causing side effects such as brittle and fragile bones and jaw osteonecrosis after tooth extraction. In orthodontics, active movement is precisely controlled by temporarily suppressing and resuming movement. BP impedes such control because of its long half-life of several years in bone. Therefore, we investigated the novel osteoclast-specific inhibitor reveromycin A (RMA), which has a short half-life in bone. We hypothesized that tooth movement could be precisely controlled through temporary discontinuation and re-administration of RMA. Osteoprotegerin-deficient mice and wild-type mice were developed as tooth movement models under constant orthodontic force. A constant orthodontic force of 10 g was induced using a nickel-titanium closed coil spring to move the maxillary first molar for 14 days. We administered BP (1.25 mg/kg) or RMA (1.0 mg/kg) continuously and then discontinued it to reveal how the subsequent movement of teeth and surrounding alveolar bone was affected. Continuous BP or RMA administration suppressed osteoclast activity and preserved alveolar bone around the roots, apparently normalizing bone metabolism. Tooth movement remained suppressed after BP discontinuation but resumed at a higher rate after discontinuation of RMA. RMA appears useful for controlling orthodontic tooth movement because it can be suppressed and resumed through administration and discontinuation, respectively. •Osteoprotegerin-deficient mice are alveolar bone models of osteoporosis or frail periodontal tissue.•Mice were developed as tooth movement models under constant orthodontic force.•Continuous reveromycin A (RMA) administration suppressed osteoclast activity.•RMA has a short half-life in bone.•RMA appears useful for controlling orthodontic tooth movement.</description><identifier>ISSN: 0889-5406</identifier><identifier>EISSN: 1097-6752</identifier><identifier>DOI: 10.1016/j.ajodo.2019.04.037</identifier><identifier>PMID: 32354441</identifier><language>eng</language><publisher>NEW YORK: Elsevier Inc</publisher><subject>Dentistry ; Dentistry, Oral Surgery &amp; Medicine ; Life Sciences &amp; Biomedicine ; Science &amp; Technology</subject><ispartof>American journal of orthodontics and dentofacial orthopedics, 2020-05, Vol.157 (5), p.680-689</ispartof><rights>2020 American Association of Orthodontists</rights><rights>Copyright © 2020 American Association of Orthodontists. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>4</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000529063100012</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c425t-aa09e3b7f7f24e6f62cbc9adcb72e8dcc0c44344bfd94305549ebfe042766653</citedby><cites>FETCH-LOGICAL-c425t-aa09e3b7f7f24e6f62cbc9adcb72e8dcc0c44344bfd94305549ebfe042766653</cites><orcidid>0000-0002-9571-4916</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ajodo.2019.04.037$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>315,782,786,3552,27931,27932,28255,46002</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32354441$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Minamoto, Chisato</creatorcontrib><creatorcontrib>Miyazawa, Ken</creatorcontrib><creatorcontrib>Tabuchi, Masako</creatorcontrib><creatorcontrib>Hirano, Miyuki</creatorcontrib><creatorcontrib>Mizuno, Manami</creatorcontrib><creatorcontrib>Yoshizako, Mamoru</creatorcontrib><creatorcontrib>Torii, Yasuyoshi</creatorcontrib><creatorcontrib>Asano, Yuichirou</creatorcontrib><creatorcontrib>Sato, Takuma</creatorcontrib><creatorcontrib>Kawatani, Makoto</creatorcontrib><creatorcontrib>Osada, Hiroyuki</creatorcontrib><creatorcontrib>Maeda, Hatsuhiko</creatorcontrib><creatorcontrib>Goto, Shigemi</creatorcontrib><title>Alteration of tooth movement by reveromycin A in osteoprotegerin-deficient mice</title><title>American journal of orthodontics and dentofacial orthopedics</title><addtitle>AM J ORTHOD DENTOFAC</addtitle><addtitle>Am J Orthod Dentofacial Orthop</addtitle><description>Osteoprotegerin-deficient mice develop severe high-turnover osteoporosis with porous low-density trabecular bone from an age-related increase in osteoclast activity and are useful alveolar bone models of osteoporosis or frail periodontal tissue. Bisphosphonate (BP), a first-line drug for osteoporosis, is bone-avid, causing side effects such as brittle and fragile bones and jaw osteonecrosis after tooth extraction. In orthodontics, active movement is precisely controlled by temporarily suppressing and resuming movement. BP impedes such control because of its long half-life of several years in bone. Therefore, we investigated the novel osteoclast-specific inhibitor reveromycin A (RMA), which has a short half-life in bone. We hypothesized that tooth movement could be precisely controlled through temporary discontinuation and re-administration of RMA. Osteoprotegerin-deficient mice and wild-type mice were developed as tooth movement models under constant orthodontic force. A constant orthodontic force of 10 g was induced using a nickel-titanium closed coil spring to move the maxillary first molar for 14 days. We administered BP (1.25 mg/kg) or RMA (1.0 mg/kg) continuously and then discontinued it to reveal how the subsequent movement of teeth and surrounding alveolar bone was affected. Continuous BP or RMA administration suppressed osteoclast activity and preserved alveolar bone around the roots, apparently normalizing bone metabolism. Tooth movement remained suppressed after BP discontinuation but resumed at a higher rate after discontinuation of RMA. RMA appears useful for controlling orthodontic tooth movement because it can be suppressed and resumed through administration and discontinuation, respectively. •Osteoprotegerin-deficient mice are alveolar bone models of osteoporosis or frail periodontal tissue.•Mice were developed as tooth movement models under constant orthodontic force.•Continuous reveromycin A (RMA) administration suppressed osteoclast activity.•RMA has a short half-life in bone.•RMA appears useful for controlling orthodontic tooth movement.</description><subject>Dentistry</subject><subject>Dentistry, Oral Surgery &amp; Medicine</subject><subject>Life Sciences &amp; Biomedicine</subject><subject>Science &amp; Technology</subject><issn>0889-5406</issn><issn>1097-6752</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>AOWDO</sourceid><recordid>eNqNkU1r2zAYgMXoWNNuv6BQfCwMe68-bR12CKFbB4Veehe2_GpTiK1OUlLy76s0WY9lF0mH59HHI0KuKDQUqPq2bvp1GEPDgOoGRAO8_UAWFHRbq1ayM7KArtO1FKDOyUVKawDQgsEncs4Zl0IIuiAPy03G2Gcf5iq4KoeQ_1RT2OGEc66GfRVxhzFMe-vnalmVIaSM4SmGjL8x-rke0XnrD_TkLX4mH12_SfjlNF-Sxx-3j6u7-v7h56_V8r62gslc9z1o5EPrWscEKqeYHazuRzu0DLvRWrBCcCEGN2rBQUqhcXAIgrVKKckvyc1x23KRv1tM2Uw-Wdxs-hnDNhnGdau6TipdUH5EbQwpRXTmKfqpj3tDwRxCmrV5DWkOIQ0IU0IW6_p0wHaYcHxz_pUrwNcj8IxDcOlQwOIbVlJLpkFxWlaUFbr7f3rl8-uHrMJ2zkX9flSx5Nx5jOakjz6izWYM_t2XvAAddacR</recordid><startdate>202005</startdate><enddate>202005</enddate><creator>Minamoto, Chisato</creator><creator>Miyazawa, Ken</creator><creator>Tabuchi, Masako</creator><creator>Hirano, Miyuki</creator><creator>Mizuno, Manami</creator><creator>Yoshizako, Mamoru</creator><creator>Torii, Yasuyoshi</creator><creator>Asano, Yuichirou</creator><creator>Sato, Takuma</creator><creator>Kawatani, Makoto</creator><creator>Osada, Hiroyuki</creator><creator>Maeda, Hatsuhiko</creator><creator>Goto, Shigemi</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>AOWDO</scope><scope>BLEPL</scope><scope>DTL</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-9571-4916</orcidid></search><sort><creationdate>202005</creationdate><title>Alteration of tooth movement by reveromycin A in osteoprotegerin-deficient mice</title><author>Minamoto, Chisato ; Miyazawa, Ken ; Tabuchi, Masako ; Hirano, Miyuki ; Mizuno, Manami ; Yoshizako, Mamoru ; Torii, Yasuyoshi ; Asano, Yuichirou ; Sato, Takuma ; Kawatani, Makoto ; Osada, Hiroyuki ; Maeda, Hatsuhiko ; Goto, Shigemi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c425t-aa09e3b7f7f24e6f62cbc9adcb72e8dcc0c44344bfd94305549ebfe042766653</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Dentistry</topic><topic>Dentistry, Oral Surgery &amp; Medicine</topic><topic>Life Sciences &amp; Biomedicine</topic><topic>Science &amp; Technology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Minamoto, Chisato</creatorcontrib><creatorcontrib>Miyazawa, Ken</creatorcontrib><creatorcontrib>Tabuchi, Masako</creatorcontrib><creatorcontrib>Hirano, Miyuki</creatorcontrib><creatorcontrib>Mizuno, Manami</creatorcontrib><creatorcontrib>Yoshizako, Mamoru</creatorcontrib><creatorcontrib>Torii, Yasuyoshi</creatorcontrib><creatorcontrib>Asano, Yuichirou</creatorcontrib><creatorcontrib>Sato, Takuma</creatorcontrib><creatorcontrib>Kawatani, Makoto</creatorcontrib><creatorcontrib>Osada, Hiroyuki</creatorcontrib><creatorcontrib>Maeda, Hatsuhiko</creatorcontrib><creatorcontrib>Goto, Shigemi</creatorcontrib><collection>Web of Science - Science Citation Index Expanded - 2020</collection><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of orthodontics and dentofacial orthopedics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Minamoto, Chisato</au><au>Miyazawa, Ken</au><au>Tabuchi, Masako</au><au>Hirano, Miyuki</au><au>Mizuno, Manami</au><au>Yoshizako, Mamoru</au><au>Torii, Yasuyoshi</au><au>Asano, Yuichirou</au><au>Sato, Takuma</au><au>Kawatani, Makoto</au><au>Osada, Hiroyuki</au><au>Maeda, Hatsuhiko</au><au>Goto, Shigemi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Alteration of tooth movement by reveromycin A in osteoprotegerin-deficient mice</atitle><jtitle>American journal of orthodontics and dentofacial orthopedics</jtitle><stitle>AM J ORTHOD DENTOFAC</stitle><addtitle>Am J Orthod Dentofacial Orthop</addtitle><date>2020-05</date><risdate>2020</risdate><volume>157</volume><issue>5</issue><spage>680</spage><epage>689</epage><pages>680-689</pages><issn>0889-5406</issn><eissn>1097-6752</eissn><abstract>Osteoprotegerin-deficient mice develop severe high-turnover osteoporosis with porous low-density trabecular bone from an age-related increase in osteoclast activity and are useful alveolar bone models of osteoporosis or frail periodontal tissue. Bisphosphonate (BP), a first-line drug for osteoporosis, is bone-avid, causing side effects such as brittle and fragile bones and jaw osteonecrosis after tooth extraction. In orthodontics, active movement is precisely controlled by temporarily suppressing and resuming movement. BP impedes such control because of its long half-life of several years in bone. Therefore, we investigated the novel osteoclast-specific inhibitor reveromycin A (RMA), which has a short half-life in bone. We hypothesized that tooth movement could be precisely controlled through temporary discontinuation and re-administration of RMA. Osteoprotegerin-deficient mice and wild-type mice were developed as tooth movement models under constant orthodontic force. A constant orthodontic force of 10 g was induced using a nickel-titanium closed coil spring to move the maxillary first molar for 14 days. We administered BP (1.25 mg/kg) or RMA (1.0 mg/kg) continuously and then discontinued it to reveal how the subsequent movement of teeth and surrounding alveolar bone was affected. Continuous BP or RMA administration suppressed osteoclast activity and preserved alveolar bone around the roots, apparently normalizing bone metabolism. Tooth movement remained suppressed after BP discontinuation but resumed at a higher rate after discontinuation of RMA. RMA appears useful for controlling orthodontic tooth movement because it can be suppressed and resumed through administration and discontinuation, respectively. •Osteoprotegerin-deficient mice are alveolar bone models of osteoporosis or frail periodontal tissue.•Mice were developed as tooth movement models under constant orthodontic force.•Continuous reveromycin A (RMA) administration suppressed osteoclast activity.•RMA has a short half-life in bone.•RMA appears useful for controlling orthodontic tooth movement.</abstract><cop>NEW YORK</cop><pub>Elsevier Inc</pub><pmid>32354441</pmid><doi>10.1016/j.ajodo.2019.04.037</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-9571-4916</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0889-5406
ispartof American journal of orthodontics and dentofacial orthopedics, 2020-05, Vol.157 (5), p.680-689
issn 0889-5406
1097-6752
language eng
recordid cdi_proquest_miscellaneous_2397688569
source Web of Science - Science Citation Index Expanded - 2020<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" />; Access via ScienceDirect (Elsevier)
subjects Dentistry
Dentistry, Oral Surgery & Medicine
Life Sciences & Biomedicine
Science & Technology
title Alteration of tooth movement by reveromycin A in osteoprotegerin-deficient mice
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-06T11%3A59%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_webof&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Alteration%20of%20tooth%20movement%20by%20reveromycin%20A%20in%20osteoprotegerin-deficient%20mice&rft.jtitle=American%20journal%20of%20orthodontics%20and%20dentofacial%20orthopedics&rft.au=Minamoto,%20Chisato&rft.date=2020-05&rft.volume=157&rft.issue=5&rft.spage=680&rft.epage=689&rft.pages=680-689&rft.issn=0889-5406&rft.eissn=1097-6752&rft_id=info:doi/10.1016/j.ajodo.2019.04.037&rft_dat=%3Cproquest_webof%3E2397688569%3C/proquest_webof%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2397688569&rft_id=info:pmid/32354441&rft_els_id=S0889540619309679&rfr_iscdi=true